ALSO NOTED: BDSI gains $30M milestone; Medicines Company files NDA; Neurogen names CEO; and much more...

> BioDelivery Sciences has pocketed a $30 million milestone payment from Meda as part of their licensing agreement for the commercialization of BEMA Fentanyl, a new pain patch for cancer patients. Report

> The Medicines Company has filed an NDA for Cleviprex, a treatment for acute hypertension. If approved, Cleviprex will be the first new treatment for acute hypertension in more than 10 years. Release

> Chutes & Ladders: Neurogen has elected Stephen R. Davis as the eventual successor to William H. Koster, the current CEO of Neurogen. Release

> A researcher has identified a method for boosting the activity of antidepression drugs--an advance that could revolutionize the way these therapies work. Report

> The Max Planck Society is considering developing a 100,000-square foot research facility in Florida Atlantic University's Jupiter campus. Report

> Emory University has launched a $50 million research initiative focused on using genetic markers to predict what diseases a patient will have--rather than waiting for those diseases to hit a patient later in life. FierceHealthcare

> Pain can be a killer. Cephalon officially warned doctors yesterday to use its opioid pain reliever Fentora very, very carefully, or patients might die. FiercePharma

And Finally... Should drug and medical device makers be required to report payments made to doctors? Poll

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.